Purpose Studies suggest that metformin, widely used for treating type 2 diabetes, possesses innate antineoplastic properties. For metabolic syndrome patients with hepatocellular carcinoma, metformin may provide antitumoral effects We evaluated the impact of metformin on tumor growth and visceral fat composition using relevant preclinical models of metabolic syndrome. Experimental Design Studies were performed in three hepatoma cell lines, in HepG2 xenograft mice fed with standard chow-diet (SC), 60% high-fat diet (HFD) or 30% fructose diet (FR), and an ex vivo model of human cultured hepatocellular carcinoma slices. Visceral fatty acid composition was analyzed by MRI. Results Metformin had a dose-dependent inhibitory effect on cell proliferation and apoptosis in vitro through the deregulation of mTOR/AMPK, AKT and ERK signaling pathways. Tumor engraftment rates were higher in HFD mice than SC mice (hepatic: 79% vs 25%, p=0.02) and FR mice (subcutaneous: 86% vs 50%, p=0.04). Subcutaneous tumor volume was increased in HFD mice (+64% vs FR and SC, p=0.03). Metformin significantly decreased subcutaneous tumor growth via cell cycle block and mTOR pathway inhibition, and also induced hypoxia and decreased angiogenesis. In ex vivo tumor slices, metformin treatment led to increased necrosis, decreased cyclin D1, and increased CA-9. Metformin caused qualitative changes in visceral fat composition of HFD mice, with decreased proportions of polyunsaturated fatty acids (14.6% ± 2.3% vs 17.9% ± 3.0%, p =0.04). Conclusions The potent antitumoral effects of metformin in multiple preclinical models implicating several molecular mechanisms provide strong rationale for clinical trials including combination studies in hepatocellular carcinoma patients.